GlassScriptPhysician profile
Amber Rose Curtis
NPI 1386215846
$3,666.03
in general payments reported to CMS, 2019-2025
19 companies · $77.34 in 2025
The $77.34 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.53 · 2022: $1,515 · 2023: $1,096 · 2024: $929 · 2025: $77.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $355.87 | 2021-2025 | Trintellix |
| Abbvie INC. | $332.75 | 2022-2025 | |
| Corium, LLC | $299.65 | 2022-2024 | Azstarys, Azstarys |
| Vanda Pharmaceuticals INC. | $293.16 | 2022-2024 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $285.56 | 2022-2024 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $282.96 | 2021-2023 | Rexulti |
| Alkermes, INC. | $278.15 | 2022-2024 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $224.31 | 2024-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $223.13 | 2022-2024 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $219.77 | 2022-2024 | Uzedy, Austedo, Austedo Xr |
| Lundbeck LLC | $196.83 | 2022-2024 | Rexulti |
| Axsome Therapeutics, INC. | $179.69 | 2023-2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.76 | 2022-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $118.43 | 2021-2022 | |
| Neuronetics, INC. | $107.84 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $57.21 | 2022 | |
| Noven Therapeutics, LLC | $44.22 | 2024 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $34.23 | 2024 | Ingrezza |
| Indivior INC. | $13.51 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.